Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2019 1
2020 1
2021 3
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW. Hilton J, et al. Among authors: veitch zw. Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2. Nat Commun. 2022. PMID: 35750695 Free PMC article.
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Veitch ZW, Shepshelovich D, Gallagher C, Wang L, Abdul Razak AR, Spreafico A, Bedard PL, Siu LL, Minasian L, Hansen AR. Veitch ZW, et al. J Natl Cancer Inst. 2021 Aug 2;113(8):980-988. doi: 10.1093/jnci/djab015. J Natl Cancer Inst. 2021. PMID: 33616650 Free PMC article.
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Janse van Rensburg HJ, Liu Z, Watson GA, Veitch ZW, Shepshelovich D, Spreafico A, Abdul Razak AR, Bedard PL, Siu LL, Minasian L, Hansen AR. Janse van Rensburg HJ, et al. Among authors: veitch zw. Br J Cancer. 2023 Sep;129(4):612-619. doi: 10.1038/s41416-023-02307-w. Epub 2023 Jul 7. Br J Cancer. 2023. PMID: 37419999 Free PMC article.
Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study.
Al-Ezzi EM, Veitch ZW, Salah SH, Van der Kwast TH, Stockley TL, Selvarajah S, Zhang T, Sridhar SS, Sacher AG, Fallah-Rad N, Kulkarni GS, Zlotta AR, Finelli A, Hansen AR. Al-Ezzi EM, et al. Among authors: veitch zw. PLoS One. 2021 Dec 1;16(12):e0259272. doi: 10.1371/journal.pone.0259272. eCollection 2021. PLoS One. 2021. PMID: 34851968 Free PMC article.
The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.
Alqaisi HA, Stecca C, Veitch ZW, Riromar J, Kaiser J, Fallah-Rad N, Jiang DM, North S, Samnani S, Alimohamed N, Sridhar SS. Alqaisi HA, et al. Among authors: veitch zw. Ther Adv Med Oncol. 2022 May 1;14:17588359221094879. doi: 10.1177/17588359221094879. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35520101 Free PMC article.
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL. Veitch ZW, et al. Br J Cancer. 2019 Aug;121(4):318-324. doi: 10.1038/s41416-019-0517-3. Epub 2019 Jul 15. Br J Cancer. 2019. PMID: 31303643 Free PMC article. Clinical Trial.
12 results